Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8N4T8

UPID:
CBR4_HUMAN

ALTERNATIVE NAMES:
3-ketoacyl-[acyl-carrier-protein] reductase beta subunit; Carbonyl reductase family member 4; Quinone reductase CBR4; Short chain dehydrogenase/reductase family 45C member 1

ALTERNATIVE UPACC:
Q8N4T8; Q8WTW8; Q96K93

BACKGROUND:
3-oxoacyl-[acyl-carrier-protein] reductase, integral to the mitochondrial fatty acid synthase (mtFAS) system, exhibits a broad substrate range, reducing 3-oxoacyl-[ACP] to (3R)-hydroxyacyl-[ACP]. Its activity is crucial for mitochondrial lipid metabolism, and its ability to reduce harmful quinones in vitro suggests a protective role against oxidative stress.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of 3-oxoacyl-[acyl-carrier-protein] reductase unveils potential pathways for developing novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.